Leerink Upgrades Illumina to Outperform | GenomeWeb

NEW YORK (GenomeWeb) – Investment bank Leerink has upgraded Illumina's stock to Outperform from Market Perform, anticipating faster than previously expected adoption of its new sequencing instrument, NovaSeq, based on a recent survey by MEDACorp that Leerink commisioned of 40 NGS labs. Leerink set a 12-month price target for Illumina shares at $195.

The investment bank also raised Illumina's 2018 revenue estimates 3 percent to $3.07 billion and its 2019 revenue estimates to $3.44 billion.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.

Mar
28
Sponsored by
Illumina

This webinar describes the optimization and validation of two commercially available next-generation sequencing assays that may be used to guide personalized cancer treatment. 

Mar
30
Sponsored by
SeraCare

Our roundtable of industry experts will provide an overview of the current regulatory landscape for clinical genomics tests.

Apr
13
Sponsored by
SeraCare

In this webinar, Gregory J. Tsongalis of Dartmouth Hitchcock Medical Center will discuss how his lab developed and validated a cancer hotspot assay. 

Apr
27
Sponsored by
SeraCare

This webinar is the third in a four-part series highlighting real-world examples of how some lab directors are bringing validated next-generation sequencing-based tests to the clinic.